ClinicalTrials.gg
CompletedNCT04534699Updated Dec 16, 2025

Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

A Phase 1 interventional study of KBP-5074 in Moderate Hepatic Impairment and Healthy, sponsored by KBP Biosciences. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by KBP Biosciences · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Nov 2020, 6 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This multiple-center, nonrandomized, open label, parallel group, single dose study will be conducted in male and female subjects with normal hepatic function or moderate (Child-Pugh Class B) hepatic impairment to evaluate the effect of hepatic impairment on the pharmacokinetics (PK) of KBP-5074.

02

Conditions studied

  • Moderate Hepatic Impairment
  • Healthy

Keywords

  • Hepatic Impairment
  • Moderate Hepatic Impairment
  • Healthy
  • KBP-5074
03

In context

Lead sponsor

KBP Biosciences is the lead sponsor of 12 studies on the registry; none are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Males or females, of any race, between 18 and 80 years of age, inclusive, at screening.
  2. between 18.0 and 40.0 kg/m2, inclusive, at screening.
  3. Subjects with normal hepatic function must be in good health.
  4. Subjects must meet the criteria for moderate hepatic impairment based on B.

Key Exclusion Criteria:

  1. Significant history or clinical manifestation of any medical history, as determined by the investigator not appropriate to participate in this study.
  2. Positive serology test results for surface antigen and/or 1/2.
  3. Participation in a clinical study involving administration of an drug (new chemical entity) in the past 30 days or 5 half-lives prior to dosing, whichever is longer.
  4. Use of mineralocorticoids or MRAs (eg, spironolactone or eplenerone) within 90 days prior to study drug administration, unless deemed acceptable by the medical monitor and sponsor.
  5. Subject has used prescription drugs within 30 days of study drug administration, with the exception of established therapy for hepatic disease and the treatment of associated disorders that have been stable for at least 30 days before study drug administration, as approved by the investigator and in consultation with the medical monitor.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Hepatic Impaired

    KBP-5074 0.5mg tablet orally, Single dose

    Drug: KBP-5074

  • Experimental
    Matched-control Healthy

    KBP-5074 0.5mg tablet orally, Single dose

    Drug: KBP-5074

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Parameter: Maximum observed concentration (Cmax)

    Maximum observed concentration (Cmax) - Plasma

    Time frame: 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, and 264 hours postdose.

  2. Pharmacokinetic Paramete: Area under the concentration-time curve from time 0 to infinity (AUC0-∞)

    Area under the concentration-time curve from time 0 to infinity (AUC0-∞) - Plasma

    Time frame: 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, and 264 hours postdose.

  3. Pharmacokinetic Parameter: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUC0-tlast)

    Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUC0-tlast) - Plasma

    Time frame: 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, and 264 hours postdose.

  4. Pharmacokinetic Parameter: Time of the maximum observed concentration (tmax)

    Time of the maximum observed concentration (tmax) - Plasma

    Time frame: 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, and 264 hours postdose.

  5. Safety of KBP-5074 by assessing the number of adverse events, laboratory abnormalities, ECGs, vital signs and physical examinations

    Incidence of severity of AEs, laboratory abnormalities (based on hematology, clinical chemistry, and urinalysis test results), ECGs, vital signs, and physical examinations

    Time frame: Up to 12 days

07

Study locations

3 sites
  • Orlando Clinical Research Center (OCRC)
    Orlando, Florida 32809, United States
  • Texas Liver Institute (TLI)
    San Antonio, Texas 78215, United States
  • Clinical Trials of Texas (CTT)
    San Antonio, Texas 78229, United States
08

References and documents

Publications

  • McCabe J, Zhang J, Yang F, Benn V. Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment. Eur J Drug Metab Pharmacokinet. 2024 Mar;49(2):229-237. doi: 10.1007/s13318-024-00879-3. Epub 2024 Feb 8. PubMed 38329646 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Nov 2020, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2020
First posted
Sep 1, 2020
StartActual
Aug 27, 2020
Primary completionActual
Nov 19, 2020
CompletionActual
Nov 19, 2020
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04534699
Lead sponsor
KBP Biosciences
Collaborators
Covance
Responsible party
Sponsor
First posted
Sep 1, 2020
Start date
Aug 27, 2020
Primary completion
Nov 19, 2020
Completion
Nov 19, 2020
Last update
Dec 16, 2025

Study contacts

James McCabe
study director · KBP Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KBP-5074

Start the discussion